Cargando…

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of highly active relapsing-remitting multiple sclerosis (MS). The principal adverse effect is the development of secondary autoimmune disorders during the immune reconstitution period after alemtuzumab, with autoim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kazakou, Paraskevi, Tzanetakos, Dimitrios, Vakrakou, Aigli G, Tzartos, John S, Anagnostouli, Maria, Koutsis, Georgios, Andreadou, Elisabeth, Evangelopoulos, Maria Eleptheria, Kilidireas, Constantinos, Zapanti, Evangelia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089514/ http://dx.doi.org/10.1210/jendso/bvab048.1727

Ejemplares similares

Thyroid autoimmunity following alemtuzumab treatment in multiple sclerosis patients: a prospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023)

Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis
por: Tzanetakos, Dimitrios, et al.
Publicado: (2022)

Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases
por: Vakrakou, Aigli G., et al.
Publicado: (2021)

Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
por: Vakrakou, Aigli G., et al.
Publicado: (2020)

A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes
por: Vakrakou, A. G., et al.
Publicado: (2018)

Heterogeneity of Baló’s concentric sclerosis: a study of eight cases with different therapeutic concepts
por: Tzanetakos, D., et al.
Publicado: (2020)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Immune Reconstitution Inflammatory Syndrome Mimicking Progressive Multifocal Leucoencephalopathy in a Multiple Sclerosis Patient Treated With Natalizumab: A Case Report and Review of the Literature
por: Evangelopoulos, Maria-Eleptheria, et al.
Publicado: (2015)

Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis
por: Vakrakou, Aigli G., et al.
Publicado: (2023)

Potential Role of Antibodies against Aquaporin-1 in Patients with Central Nervous System Demyelination
por: Pechlivanidou, Maria, et al.
Publicado: (2023)

SAT-518 Progression of Graves Disease to Hashimoto’s Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis
por: Rapier, Brandon, et al.
Publicado: (2020)

An Unusual Etiology of Graves’ Disease: Alemtuzumab
por: Santiago Carrion, Ada Marie, et al.
Publicado: (2021)

Cerebrospinal Fluid Anti-Neuronal Autoantibodies in COVID-19-Associated Limbic Encephalitis with Acute Cerebellar Ataxia and Myoclonus Syndrome: Case Report and Literature Review
por: Yiannopoulou, Konstantina, et al.
Publicado: (2023)

SAT-476 Alemtuzumab Induced Graves Disease
por: Caputi, Rafael C, et al.
Publicado: (2020)

An Updated Evaluation of Intrathecal IgG Synthesis Markers in Relation to Oligoclonal Bands
por: Boufidou, Fotini, et al.
Publicado: (2023)

Early metabolic alterations in the normal‑appearing grey and white matter of patients with clinically isolated syndrome suggestive of multiple sclerosis: A proton MR spectroscopic study
por: Tzanetakos, Dimitrios, et al.
Publicado: (2023)

The mTOR Signaling Pathway in Multiple Sclerosis; from Animal Models to Human Data
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

ODP523 Thyroid Storm in a Patient With Alemtuzumab Induced Graves’ Disease
por: AlShehri, Sara, et al.
Publicado: (2022)

Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels
por: Markianos, Manolis, et al.
Publicado: (2013)

Neuromyelitis Optica Spectrum Disease with Positive Autoimmune Indices: A Case Report and Review of the Literature
por: Evangelopoulos, M. E., et al.
Publicado: (2011)

Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2014)

Moyamoya Disease May Mimic Multiple Sclerosis?
por: Spanou, Ioanna, et al.
Publicado: (2019)

Central Nervous System Demyelination in a Charcot-Marie-Tooth Type 1A Patient
por: Koros, Christos, et al.
Publicado: (2013)

Novel CSF Biomarkers Tracking Autoimmune Inflammatory and Neurodegenerative Aspects of CNS Diseases
por: Kapaki, Elisabeth, et al.
Publicado: (2022)

MON-596 Male Individuals with Autoimmune Thyroid Disease Present Higher Risk for Clustering Other Non-Thyroidal Autoimmune Diseases
por: Lopes, Fernanda, et al.
Publicado: (2019)

Neuronal and Neuroaxonal Damage Cerebrospinal Fluid Biomarkers in Autoimmune Encephalitis Associated or Not with the Presence of Tumor
por: Vakrakou, Aigli G., et al.
Publicado: (2022)

SUN-502 Graves’Disease and Autoimmune Hepatitis: Management Challenges
por: Soares, Maria Marta Sarquis, et al.
Publicado: (2020)

Multiple Sclerosis: Shall We Target CD33?
por: Siokas, Vasileios, et al.
Publicado: (2020)

Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece
por: Dardiotis, Efthymios, et al.
Publicado: (2022)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

A Grave Case of COVID-19: SARS-CoV-2 Induced Autoimmune Hyperthyroidism
por: Matos, Moises, et al.
Publicado: (2021)

Homonymous hemianopsia as the leading symptom of a tumor like demyelinating lesion: a case report
por: Evangelopoulos, Maria Eleptheria, et al.
Publicado: (2009)

SUN-567 Moyamoya and Autoimmune Graves' Disease
por: Elagi, Daniyah, et al.
Publicado: (2019)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

SAT-582 Autoimmune Hepatitis Presenting with Graves Disease
por: Coy, Andres, et al.
Publicado: (2019)

FRI567 Insulin Autoimmune Syndrome And Grave’s Disease
por: Skariah, Annie M, et al.
Publicado: (2023)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sq41vi4s43iuaj7gpgfmahog6q